Delayed Diagnosis of Prostate Cancer With Neuroendocrine Differentiation After Laser TURP

Urology

Volumn 72, Issue 4, 2008, Pages 948.e11-948.e12

  Meeks, Joshua J ^a   Habermacher, Geoffrey M ^a   Le, Brian ^a   Smith, Norm D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CYSTOSCOPY; DELAYED DIAGNOSIS; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; URINARY TRACT OBSTRUCTION;

EID: 52949110529     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.01.007     Document Type: Article

References (10)

1. Gupta N., Sivaramakrishna, Kumar R., et al. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 97 (2006) 85-89
2. Talic R.F., and Al Rikabi A.C. Transurethral vaporization-resection of the prostate versus standard transurethral prostatectomy: comparative changes in histopathological features of the resected specimens. Eur Urol 37 (2000) 301-305
3. Descazeaud A., Peyromaure M., Salin A., et al. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. Eur Urol 53 (2008) 355-362
4. Hammadeh M.Y., Madaan S., Hines J., et al. 5-Year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 61 (2003) 1166-1171
5. Westenberg A., Gilling P., Kennett K., et al. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup. J Urol 172 (2004) 616-619
6. Nuhoglu B., Ayyildiz A., Fidan V., et al. Transurethral electrovaporization of the prostate: is it any better than standard transurethral prostatectomy? 5-year follow-up. J Endourol 19 (2005) 79-82
7. Yu X., McBean A.M., and Caldwell D.S. Unequal use of new technologies by race: the use of new prostate surgeries (transurethral needle ablation, transurethral microwave therapy and laser) among elderly Medicare beneficiaries. J Urol 175 (2006) 1830-1835
8. Das A., Kennett K.M., Sutton T., et al. Histologic effects of holmium:YAG laser resection versus transurethral resection of the prostate. J Endourol 14 (2000) 459-462
9. Culine S., El Demery M., Lamy P.-J., et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178 (2007) 844-848
10. Zhang G., Wasserman N.F., Sidi A.A., et al. Long-term followup results after expectant management of stage A1 prostatic cancer. J Urol 146 (1991) 99-103